Chemotherapy plus immunotherapy for advanced soft-tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests a combination of chemotherapy drugs (Adriamycin and ifosfamide) together with an immunotherapy drug (sintilimab) for advanced soft-tissue sarcoma that can’t be removed by surgery or has stopped responding to standard treatment. It aims to shrink tumors and help control the cancer by boosting the immune system along with chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or non-surgical soft-tissue sarcoma proven by pathology (biopsy), and standard treatment either failed, isn’t available for your type, or you can’t tolerate it.
- Your cancer has spread or is not removable (on scans), and you have at least one measurable tumor spot that can be accurately measured on CT or MRI.
- You are age 14–70, and your general ability score (ECoG) is 0–1 with an expected survival of more than 3 months.
- Your key blood and organ tests are strong enough before starting (enough hemoglobin, neutrophils, platelets; acceptable liver and kidney tests; and heart function with ejection fraction at least 50%).
- You have not had prior anti–PD-1/PD-L1 immunotherapy (like drugs targeting these checkpoints).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests toripalimab (an immune therapy) combined with CAV/IE chemotherapy for certain advanced or non-surgically removable sarcomas. It may help shrink tumors and slow disease when standard treatments have failed or don’t exist.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.